Miltefosine enhances infectivity of a miltefosine-resistant Leishmania infantum strain by attenuating its innate immune recognition

BACKGROUND: Miltefosine (MIL) is currently the only oral drug available to treat visceral leishmaniasis but its use as first-line monotherapy has been compromised by an increasing treatment failure. Despite the scarce number of resistant clinical isolates, MIL-resistance by mutations in a single ami...

Descripción completa

Detalles Bibliográficos
Autores principales: Bulté, Dimitri, Van Bockstal, Lieselotte, Dirkx, Laura, Van den Kerkhof, Magali, De Trez, Carl, Timmermans, Jean-Pierre, Hendrickx, Sarah, Maes, Louis, Caljon, Guy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330912/
https://www.ncbi.nlm.nih.gov/pubmed/34292975
http://dx.doi.org/10.1371/journal.pntd.0009622

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330912/
https://www.ncbi.nlm.nih.gov/pubmed/34292975
http://dx.doi.org/10.1371/journal.pntd.0009622

Ejemplares similares